MedTrace Logo

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07066657 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2026-02-17

No results posted yet for this study

Summary

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

MRG007

MRG007 will be administrated as specified in the protocol.

Sponsors & Collaborators

  • Lepu Biopharma Co., Ltd.

    collaborator INDUSTRY

  • ArriVent BioPharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2029-05-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07066657 on ClinicalTrials.gov